Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022
Enrollment on pace, with over 30% enrolled in the United States
Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023
CUPERTINO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals has recently announced a global enrollment update for their pivotal Phase 3 RECOVER study, which is evaluating the effectiveness of brilaroxazine for schizophrenia. Enrollment is currently ongoing at multiple sites in the United States and Europe, with site initiation in Asia expected to begin in November 2022.
Despite the challenges presented by the ongoing global pandemic, enrollment is on pace with over 30% of patients already enrolled in the United States. This progress is a testament to the dedication of the researchers and healthcare professionals involved in the study, as well as the willingness of patients to participate in potentially life-changing research.
The topline data for the RECOVER study, which will provide key insights into the effectiveness of brilaroxazine for treating schizophrenia, is expected to be released in mid-2023. This data has the potential to shape the future of schizophrenia treatment and improve the lives of countless individuals living with this challenging mental health condition.
How will this affect me?
If you or a loved one are living with schizophrenia, the results of the RECOVER study could have a significant impact on treatment options and outcomes. Brilaroxazine has the potential to be a game-changing medication for managing the symptoms of schizophrenia, and the topline data expected in mid-2023 will provide valuable insights into its efficacy and safety.
How will this affect the world?
The findings of the RECOVER study have the potential to revolutionize the treatment of schizophrenia on a global scale. With millions of people worldwide affected by this complex and often debilitating condition, the development of new and more effective treatments is crucial. If brilaroxazine proves to be a safe and effective option for managing schizophrenia symptoms, it could offer hope to individuals, families, and healthcare systems around the world.
Conclusion
The ongoing progress of the RECOVER study represents a beacon of hope for individuals living with schizophrenia and their loved ones. The dedication and hard work of the researchers and healthcare professionals involved in this groundbreaking research are paving the way for advancements in the treatment of mental health conditions. As we eagerly await the topline data expected in mid-2023, we can look forward to the potential of brilaroxazine to make a positive impact on the lives of those affected by schizophrenia.
